Is obeticholic acid effective for patients with liver cirrhosis?

Liver cirrhosis, as a chronic liver disease caused by a variety of factors, leads to gradual fibrosis and hardening of liver tissue, seriously affecting the normal function of the liver. During the treatment process, patients and doctors often seek various possible treatments to alleviate the condition and control the progression of the disease. Obeticholic acid (Obeticholic acid), as an innovative treatment drug for liver diseases, will naturally attract the attention of patients. So, can patients with cirrhosis use obeticholic acid?

Obeeticholic acid is a specially designed synthetic bile acid that has a structure similar to bile acid found naturally in the human body. It plays an important regulatory role within the liver by activating the farnesoid X receptor (FXR). This activation can affect the synthesis and excretion of bile acids, thereby having a positive impact on pathological changes in the liver.

In the treatment of primary biliary cholangitis (PBC), obeticholic acid has demonstrated its unique efficacy. PBC is an autoimmune disease that causes damage to the small bile ducts in the liver, leading to liver fibrosis and cirrhosis. Obeticholic acid reduces the burden on the liver by regulating the metabolism of bile acids, thereby helping to improve the symptoms and quality of life of PBC patients.

However, the therapeutic effect of obeticholic acid on non-primary biliary cirrhosis (such asNASH and other types of cirrhosis) is unclear. NASH is a disease closely related to obesity and metabolic disorders, which is usually accompanied by steatosis, inflammation and fibrosis of the liver. Although studies have shown that FXR agonists (such as obeticholic acid) can reduce liver inflammation and fibrosis in NASH models, these results still require further clinical validation.